MSLN Knockout HEK293T Cell Line

The choice depends on whether you are studying MSLN (mesothelin)'s role as a GPI-anchored tumor-associated antigen overexpressed in mesothelioma, pancreatic, ovarian, and lung adenocarcinoma or its emerging roles in CA-125/MUC16 binding and cancer cell adhesion. The Knockout line is the standard tool for asking whether MSLN is required for these processes — MSLN is processed from a 71 kDa precursor into a soluble MPF (megakaryocyte potentiating factor) and a cell-surface 40 kDa mesothelin retained on the cell membrane via GPI anchor. Overexpression is useful for studying MSLN in cancer-relevant contexts. For cancer immunotherapy research, the EDITGENE MSLN Knockout in HEK293T is uniquely valuable — HEK293T's very high transfection efficiency supports systematic structure-function studies and antibody validation. MSLN is a major target for CAR-T cells, antibody-drug conjugates (anetumab ravtansine), bispecific antibodies, and immunotoxins (LMB-100/SS1P) — the knockout is the gold-standard negative control for MSLN-targeted therapeutic validation. Rescue with wild-type or signaling-deficient MSLN enables structure-function studies. MSLN binds CA-125/MUC16 — this interaction is implicated in peritoneal metastasis.

Primary applications: • Anti-MSLN CAR-T cell validation: critical genetic negative control for mesothelin-specific CAR-T cells in mesothelioma, pancreatic, and ovarian cancer development. • MSLN-targeted ADC specificity: anetumab ravtansine (anti-MSLN-DM4) and other mesothelin-ADC specificity testing. • MSLN-MUC16 interaction: in heterologous co-culture systems, characterization of MSLN-CA125/MUC16 binding given its role in peritoneal metastasis. • Immunotoxin pharmacology: LMB-100/SS1P (Pseudomonas exotoxin A-based anti-mesothelin immunotoxin) specificity testing. EDITGENE recommends this model for researchers investigating mesothelin-targeted cancer immunotherapy validation and MSLN-MUC16 cancer biology.

Yes. MSLN rescue experiments require attention to GPI-anchored protein topology: • Construct design: use a codon-modified MSLN sequence with a small N-terminal or internal tag (FLAG, HA) — MSLN has C-terminal GPI signal that is cleaved during processing, so C-terminal tags will be lost. • Surface localization validation: confirm GPI-anchored plasma membrane localization by cell surface staining and PI-PLC sensitivity before functional assays. • Furin processing: MSLN is processed by furin into MPF (released) and the C-terminal 40 kDa MSLN (cell-surface) — rescue interpretation considers processing. • Functional readout: rescue should restore CA-125/MUC16 binding (in vitro binding or co-culture assays) and antibody/CAR-T recognition for therapeutic validation. HEK293T transduces with very high efficiency and supports systematic rescue experiments — ideal for MSLN-targeted therapeutic specificity testing.